Stock Updates

Is this Large Market Cap Stock target price reasonable for United Therapeutics Corporation (NASDAQ:UTHR)?

The company in question is, United Therapeutics Corporation (NASDAQ:UTHR) currently with a stock price of 117.52 (-0.06% today). The market cap for United Therapeutics Corporation is 5209.24, and is in the sector Healthcare, and Drug Manufacturers РOther industry. The target price for United Therapeutics Corporation is 130. Currently United Therapeutics Corporation is trading with a P/E of 5.71, and a forward P/E of 8.57. Average volume for United Therapeutics Corporation is 527.62 and so far today it is 270038.

Performance in the last year for United Therapeutics Corporation has been -4.62%. For EPS growth, United Therapeutics Corporation has seen a growth of 102.60%, and is looking to grow in the next year to -13.30%. More long term stats show that EPS growth has been 46.80% over the last five years and could be -2.30% for the next five years. United Therapeutics Corporation has seen sales growth quarter over quarter at 18.80%, with EPS growth quarter over quarter at 129.90%. The 20-day simple moving average is -4.57%, with the 200-day simple moving average coming to -1.84%.

Since the IPO date for United Therapeutics Corporation on the 6/17/1999, United Therapeutics Corporation has seen performance year to date to be -24.92%. With United Therapeutics Corporation trading at 117.52, the dividend yield is *TBA, and the EPS is 20.58.

So could United Therapeutics Corporation, be undervalued? Well as said before P/E is 5.71. The PEG is *TBA, P/S is 3.31 and the P/B is at 2.87. The P/cash is 5.51, with P/free cash flow at 12.32.

United Therapeutics Corporation ability to deal with debt shows that the current ratio is 4.5, and the quick ratio is 4.2. This is with long term debt/equity at 0, and total debt/equity at 0.

In terms of margins, United Therapeutics Corporation has a gross margin of 96.60%, an operating margin of 75.70% and a profit margin of 64.30%.Payout ratio for United Therapeutics Corporation is 0.00%. Return on assets come to 46.30% with return on investment coming to 19.10%.

Insider ownership for United Therapeutics Corporation, is at 0.10% and institutional ownership comes to 94.00%. Outstanding shares are at 44.3. While shares float is 42.78. The float short is currently 17.39%, and short ratio is 14.1.

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.

About the author

Peter Clarke

Leave a Comment